Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year

Executive Summary

CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.

You may also be interested in...



UK Early Access Granted For Argenx’s Generalized Myasthenia Gravis Treatment

Patients in the UK with generalized myasthenia gravis are being allowed to receive argenx’s yet-to-be approved drug efgartigimod.

Finance Watch: Days Of Reckoning As Biopharma Valuations, Fundraising Opportunities Fluctuate

Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.

Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims

US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel